What are the clinical practice guidelines for the management of premenstrual dysphoric disorder (PMDD)?

Clinical Practice Guidelines for PMDD

First-line treatment for PMDD is selective serotonin reuptake inhibitors (SSRIs), which should be initiated either continuously throughout the menstrual cycle or during the luteal phase only, with continuous dosing showing superior efficacy. 1

Diagnostic Requirements Before Treatment

Diagnosis requires prospective daily symptom tracking across at least two menstrual cycles to confirm luteal-phase-specific symptoms that remit with menses 2. This distinguishes PMDD from premenstrual exacerbation of underlying mood disorders, which affects 50-60% of individuals with mood disorders and requires different management 2.

First-Line Pharmacologic Treatment: SSRIs

Recommended Agents and Dosing

The following SSRIs have the strongest evidence base 1, 3:

• Sertraline 50-150 mg/day
• Fluoxetine 10-20 mg/day
• Escitalopram 10-20 mg/day
• Paroxetine 12.5-25 mg/day (controlled-release)

Dosing Strategy

Continuous administration (daily throughout the entire month) is more effective than luteal-phase-only dosing (SMD -0.69 vs -0.39, P=0.03) 3. However, luteal-phase dosing (from ovulation to menses onset) remains a viable option for patients concerned about medication exposure or side effects 4, 5.

SSRIs reduce overall premenstrual symptoms with moderate certainty (SMD -0.57,95% CI -0.72 to -0.42) 3.

Second-Line Pharmacologic Treatment: Hormonal Contraceptives

Combined oral contraceptives containing drospirenone (3 mg drospirenone + 20 mcg ethinyl estradiol, 24 days active/4 days inactive) represent an effective alternative when SSRIs are ineffective, contraindicated, or when contraception is desired 1, 6, 7.

Refractory Cases

For severe, treatment-resistant PMDD:

• GnRH agonists with add-back hormone therapy 6
• Surgical management (bilateral oophorectomy) for cases refractory to all medical management 1, 6

Non-Pharmacologic Interventions

Evidence-Based Approaches

Cognitive behavioral therapy (CBT) is recommended as either monotherapy for mild-to-moderate symptoms or adjunctive therapy with SSRIs 1, 7. CBT effectively reduces functional impairment, depressed mood, anxiety, mood swings, irritability, and interpersonal conflict 7.

Supportive Measures

• Exercise and lifestyle modifications should be recommended for all patients as foundational interventions 1, 5
• Anxiolytics, spironolactone, and NSAIDs can provide symptomatic relief for specific symptoms 5

Multimodal Treatment Algorithm

1. Confirm diagnosis with prospective symptom tracking (2+ cycles)
2. Initiate SSRI (continuous dosing preferred) OR CBT for mild-moderate symptoms
3. If partial response: Optimize SSRI dose or add CBT
4. If inadequate response: Switch to alternative SSRI or add drospirenone-containing OCP
5. If refractory: Consider GnRH agonist or psychiatric consultation
6. If all medical management fails: Surgical consultation for definitive treatment

Critical Safety Considerations

Common SSRI Adverse Effects (NNTH)

SSRIs increase risk of 3:

• Nausea (OR 3.30) - most common
• Sexual dysfunction/decreased libido (OR 2.32)
• Insomnia (OR 1.99)
• Asthenia/decreased energy (OR 3.28)
• Somnolence/decreased concentration (OR 3.26)

Important Clinical Caveat

PMDD is associated with elevated suicidality risk 2. Screen for suicidal ideation at each visit, particularly during the luteal phase.

Distinguishing PMDD from Premenstrual Exacerbation

Do not confuse PMDD with premenstrual exacerbation (PME) of underlying mood/anxiety disorders. PME requires treatment of the underlying condition with continuous medication rather than luteal-phase-only dosing 4. This distinction requires prospective tracking showing complete symptom remission in the follicular phase for PMDD diagnosis 2.